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soriasis is a Th1/Th17 chronic immune-
mediated disease, characterized by increased
levels of tumor necrosis factor (TNF)-alfa.
TNF-alfa blockers including adalimumab have been
widely used to treat immune-mediated diseases such
as inflammatory bowel disease, psoriasis, rheuma-
toid arthritis, and psoriatic arthritis. TNF-alfa plays a
central role in the inflammation and cellular immune
response and TNF inhibitors have all been associ-
ated with malignancy and infection, especially when
used in combination with other immune suppres-
sants.1 Here we describe a patient with psoriasis
treated with adalimumab who developed dermato-
fibrosarcoma protuberans (DFSP) with fibrosarcom-
atous change.
CASE REPORT
A 34-year-old Caucasian man with a history of
psoriasis was treated with adalimumab injections,
subcutaneous 40 mg every 2 weeks for the past
2 years. The patient was born and raised in New
Jersey. Hewas overweight with a bodymass index of
29 but otherwise healthy. His medical history was
significant only for psoriasis and removal of an
atypical nevus about a decade earlier. HIV antibody
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Two years after starting treatment with adalimu-
mab the patient presented to his dermatologist with
amass on the left upper aspect of his back. Themass
was first noted by the patient the year before, but
the patient noticed rapid growth in the past
2 months. The patient did not recall any trauma or
burn to this area.
The physical examination was remarkable for a 3-
to 4-cm soft, rubbery, mobile, subcutaneous mass on
the upper aspect of the back. The overlying skin was
intact and had no scar. The initial excision of this
revealed a nonencapsulated but well-defined tumor
that extended beyond the expected clinical size. The
histopathologic examination revealed a densely
cellular nonpigmented spindle cell tumor in the
dermis and subcutaneous tissue not associated with
the overlying epidermis. The tumor showed some
areas of storiform (cartwheel) arrangement (Fig 1)
and other areas showed elongated fascicles with a
herringbone appearance (Fig 2). Mitoses were easily
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Fig 2. Dermatofibrosarcoma protuberans with fibrosar-
comatous changes. Representative section shows elon-
gated fascicles of tumor cells with herringbone
appearance. (Hematoxylin-eosin stain; original magnifica-
tion: 320.)
Fig 1. Dermatofibrosarcoma protuberans. Representative
section shows an area of the tumor with storiform
(cartwheel) arrangement of cells. (Hematoxylin-eosin
stain; original magnification: 320.)
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Belyaeva et al 273with CD34 and CD10. Part of the tumor was negative
for CD34 stain, and the mitotic count in that area was
high with up to 36 mitoses per 10 high power field
(HPF). The histologic features were most compatible
with DFSP showing fibrosarcomatous change.
Adalimumab was discontinued and the tumor was
treated with Mohs micrographic surgery, yielding a
defect of 9.4 3 6.7 cm that was successfully closed
with a rhombic flap.
DISCUSSION
DFSP is an unusual, infiltrative, locally aggressive
cutaneous neoplasm of intermediate malignancy.
Most frequently it occurs with a slight predominance
in young adult men on the trunk and proximal
extremities. It arises from the dermis and invades
deeper subcutaneous tissues but, despite its local
invasiveness, it rarely metastasizes (5% of cases).2
Fibrosarcomatous change in DFSP is a form of tumorprogression that carries an increased risk of
metastases.3
The origin of DFSP is unknown.2 It is not clear
whether in our case the development of this tumor
was triggered or caused by TNF-alfa blocker therapy
or represents an independent event. One might also
speculate that the fibrosarcomatous changes may be
related to the adalimumab therapy. To our knowl-
edge, despite the intense interest in evaluating the
risk of cancer associated with TNF inhibitors, there
were no reported cases of DFSP or DSFP with
fibrosarcomatous features in patients on TNF-alfa
blocker treatment. However, there are reported
cases of occurrence of DFSP in immunocompro-
mised patients. A case of locally invasive DFSP has
been described in a patient 4 years after a successful
kidney transplantation.4 Occurrence of DFSP in
patients with HIV has been reported.5 An unex-
pected high incidence of this tumor was observed in
children with adenosine deaminase-deficient severe
combined immunodeficiency.6
Given the rarity of DFSP and its prior association
with immune suppression, a single case in a patient
treated with a TNF inhibitor may suggest a safety
signal. Additional reports will be necessary for
further investigation. Patients receiving chronic
TNF inhibitors should be carefully monitored for
skin malignancies.7
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